This company listing is no longer active
Nuvo Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Información clave
-26.5%
Tasa de crecimiento de los beneficios
-26.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 7.3% |
Tasa de crecimiento de los ingresos | 26.3% |
Rentabilidad financiera | 178.8% |
Margen neto | 20.9% |
Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Nuvo Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 22 | 72 | 15 | 26 | 0 |
30 Jun 22 | 71 | -3 | 25 | 0 |
31 Mar 22 | 70 | -12 | 25 | 0 |
31 Dec 21 | 69 | -32 | 24 | 0 |
30 Sep 21 | 68 | -24 | 24 | 0 |
30 Jun 21 | 68 | -9 | 23 | 0 |
31 Mar 21 | 64 | -20 | 23 | 0 |
31 Dec 20 | 74 | -4 | 23 | 0 |
30 Sep 20 | 76 | -7 | 22 | 0 |
30 Jun 20 | 78 | 0 | 0 | 0 |
31 Mar 20 | 79 | 9 | 26 | 0 |
31 Dec 19 | 70 | 3 | 28 | 0 |
30 Sep 19 | 55 | -1 | 21 | 0 |
30 Jun 19 | 41 | -8 | 44 | 0 |
31 Mar 19 | 30 | -13 | 14 | 0 |
31 Dec 18 | 20 | -6 | 9 | 0 |
30 Sep 18 | 20 | -2 | 11 | 0 |
30 Jun 18 | 18 | 0 | 8 | 0 |
31 Mar 18 | 15 | -1 | 8 | 0 |
31 Dec 17 | 18 | 2 | 7 | 0 |
30 Sep 17 | 19 | 4 | 6 | 0 |
30 Jun 17 | 21 | 5 | 6 | 0 |
31 Mar 17 | 26 | 8 | 6 | 0 |
31 Dec 16 | 27 | 7 | 7 | 0 |
30 Sep 16 | 29 | 10 | 6 | 0 |
30 Jun 16 | 29 | 11 | 6 | 0 |
31 Mar 16 | 24 | 8 | 5 | 0 |
Ingresos de calidad: 23N has high quality earnings.
Margen de beneficios creciente: 23N became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 23N has become profitable over the past 5 years, growing earnings by -26.5% per year.
Acelerando crecimiento: 23N has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: 23N has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Rentabilidad financiera
Alta ROE: Whilst 23N's Return on Equity (178.77%) is outstanding, this metric is skewed due to their high level of debt.